[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "Study Design",
      "Rating Quality",
      "Strength Determinants",
      "Strength and Implications of Recommendation"
    ],
    "rows": [
      [
        "Randomized controlled trial",
        "High",
        "Quality of evidence",
        "Strong"
      ],
      [
        "Moderate",
        "Balance of benefits and harms",
        "Most people would want courseMost people should take courseCan be adapted as policy in most cases"
      ],
      [
        "Low",
        "Patient values and preferences"
      ],
      [
        "Observational",
        "Very low",
        "Resources and costs",
        "Conditional"
      ],
      [
        "Feasibility",
        "Many people would select courseRequires decision aids and shared decision‐makingDebatable policy choice"
      ],
      [
        "Acessibility"
      ],
      [
        "Equity"
      ]
    ],
    "row_count": 7,
    "column_count": 4
  },
  {
    "table_index": 3,
    "headers": [
      "Condition",
      "Definition"
    ],
    "rows": [
      [
        "AIH",
        "Characteristic histologic abnormalities (lymphoplasmacytic interface hepatitis), elevated AST, ALT, and total IgG and the presence of one or more characteristic autoantibodies"
      ],
      [
        "Inactive cirrhosis",
        "Absence of inflammatory infiltrates in both portal tracts and fibrous bands in cirrhosis"
      ],
      [
        "Acute severe AIH",
        "Jaundice, INR > 1.5 < 2, no encephalopathy; no previously recognized liver disease370"
      ],
      [
        "ALF",
        "INR ≥ 2; hepatic encephalopathy within 26 weeks of onset of illness; no previously recognized liver disease100"
      ],
      [
        "Biochemical remission",
        "Normalization of serum AST, ALT, and IgG*levels"
      ],
      [
        "Histological remission",
        "Absence of inflammation in liver tissue after treatment"
      ],
      [
        "Treatment failure",
        "Worsening laboratory or histological findings despite compliance with standard therapy"
      ],
      [
        "Incomplete response",
        "Improvement of laboratory and histological findings that are insufficient to satisfy criteria for remission"
      ],
      [
        "Relapse",
        "Exacerbation of disease activity after induction of remission and drug withdrawal (or nonadherence)"
      ],
      [
        "Treatment intolerance",
        "Inability to continue maintenance therapy due to drug‐related side effects"
      ]
    ],
    "row_count": 10,
    "column_count": 2
  },
  {
    "table_index": 4,
    "headers": [
      "Features",
      "Type 1 AIH",
      "Type 2 AIH"
    ],
    "rows": [
      [
        "Frequency",
        "US adults, 96%61",
        "US children, 9%‐12%14"
      ],
      [
        "UK children, 38%13"
      ],
      [
        "Age at presentation",
        "Peripubertal and adults",
        "Usually under 14 years153"
      ],
      [
        "Mode of presentation",
        "Chronic symptoms common",
        "Acute onset (~40%)"
      ],
      [
        "Ascites or GI bleeding rare",
        "Acute liver failure possible555"
      ],
      [
        "Asymptomatic in 25%‐34%",
        "Relapse frequent108"
      ],
      [
        "Acute in 25%‐75%",
        ""
      ],
      [
        "Acute severe in 2%‐6%",
        ""
      ],
      [
        "Laboratory features",
        "Hypergammaglobulinemia",
        "IgA levels may be reduced153"
      ],
      [
        "Autoantibodies",
        "ANA",
        "Anti‐LKM1"
      ],
      [
        "SMA, anti‐actin",
        "[Anti‐LC1, Anti‐LKM3]"
      ],
      [
        "SLA",
        ""
      ],
      [
        "Concurrent immune diseases",
        "Autoimmune thyroiditis",
        "Autoimmune thyroiditis"
      ],
      [
        "Rheumatic diseases",
        "Diabetes mellitus"
      ],
      [
        "IBD",
        "Vitiligo"
      ],
      [
        "Autoimmune overlap with PSC (ASC in children)",
        "Common in children",
        "Rare"
      ],
      [
        "Atypical pANCA‐positive",
        "Atypical pANCA‐negative"
      ],
      [
        "Overlap with PBC",
        "Seen in adults (not children)",
        "Not reported"
      ],
      [
        "Cirrhosis at presentation",
        "Adults, 28%‐33% (especially elderly)",
        "Rare"
      ],
      [
        "Children, ≤33%"
      ],
      [
        "Remission after drug withdrawal",
        "Possible",
        "Rare, usually need long‐term immunosuppression"
      ]
    ],
    "row_count": 21,
    "column_count": 3
  },
  {
    "table_index": 5,
    "headers": [
      "Antibody",
      "Target Antigen",
      "Diagnostic Value"
    ],
    "rows": [
      [
        "ANA",
        "Chromatin, ribonucleoproteins557",
        "Type 1 AIH56"
      ],
      [
        "SMA",
        "Filamentous actin (F‐actin), vimentin, desmin81",
        "Type 1 AIH56"
      ],
      [
        "LKM1",
        "Cytochrome P450 2D6 (CYP2D6)559",
        "Type 2 AIH153"
      ],
      [
        "SLA",
        "Sep (O‐phosphoserine) transfer RNA:Sec (selenocysteine) transfer RNA synthase560",
        "Type 1 AIH69"
      ],
      [
        "Severe AIH70"
      ],
      [
        "Predicts relapse after treatment73"
      ],
      [
        "Associated with poor outcome70"
      ],
      [
        "p‐ANCA (atypical)",
        "Β‐tubulin isotype 577",
        "Type 1 AIH75"
      ],
      [
        "",
        "Nuclear lamina proteins565",
        "PSC566"
      ],
      [
        "",
        "ASC108"
      ],
      [
        "Actin",
        "Filamentous (F) actin81",
        "Type 1 AIH81"
      ],
      [
        "α‐Actinin",
        "Filamentous actin cross‐linking proteins568",
        "Investigational84"
      ],
      [
        "",
        "",
        "Type 1 AIH85"
      ],
      [
        "",
        "",
        "Prognostic biomarker85"
      ],
      [
        "LKM3",
        "UDP glucuronosyltransferase family 190",
        "Type 2 AIH90"
      ],
      [
        "",
        "",
        "Hepatitis D90"
      ],
      [
        "LC‐1",
        "Formiminotransferase cyclodeaminase569",
        "Type 2 AIH569"
      ],
      [
        "LM",
        "Cytochrome P450 1A2572",
        "Dihydralazine‐induced hepatitis574"
      ],
      [
        "",
        "",
        "APECED hepatitis575"
      ],
      [
        "AMA",
        "E2‐subunits of pyruvate dehydrogenase complex576",
        "PBC576"
      ],
      [
        "PBC–AIH overlap syndrome177"
      ],
      [
        "Type 1 AIH183"
      ]
    ],
    "row_count": 22,
    "column_count": 3
  },
  {
    "table_index": 6,
    "headers": [
      "Definite Association",
      "Probable Association",
      "Possible Association"
    ],
    "rows": [
      [
        "Minocycline187",
        "Propylthiouracil579",
        "Ipilimumab (anti‐CTLA‐4)581"
      ],
      [
        "Nitrofurantoin187",
        "Isoniazid582",
        "Tremelimumab (anti‐CTLA‐4)581"
      ],
      [
        "Infliximab206",
        "Diclofenac583",
        "Nivolumab (anti‐PD‐1)581"
      ],
      [
        "Alpha‐methyldopa585",
        "Etanercept216",
        "Pembroluzimab (anti‐PD‐1)230"
      ],
      [
        "Adalimumab216",
        "Atorvastatin592",
        "Atezolizumab (anti‐PD‐L1)581"
      ],
      [
        "Halothane596",
        "Rosuvastatin598",
        "Black cohosh (herbal medicine)599"
      ],
      [
        "Oxyphenisatin*601",
        "Clometacine602",
        "Dai‐saiko‐to (herbal medicine)604"
      ],
      [
        "Dihydralazine*573",
        "",
        "Germander (herbal medicine)606"
      ],
      [
        "Tienilic acid*607",
        "",
        "Hydroxycut (nutritional supplement)608"
      ],
      [
        "",
        "",
        "Trichloroethylene (toxin)609"
      ],
      [
        "",
        "",
        "Papaverine610"
      ],
      [
        "",
        "",
        "Indomethacin611"
      ],
      [
        "",
        "",
        "Imatinab612"
      ]
    ],
    "row_count": 13,
    "column_count": 3
  },
  {
    "table_index": 7,
    "headers": [
      "Clinical Features",
      "Drug Induced AIH‐Like Injury",
      "AIH"
    ],
    "rows": [
      [
        "Gender",
        "Mainly women187",
        "Female predominance, but men also affected2"
      ],
      [
        "Acute onset",
        "Majority (>60%)231",
        "<20%2"
      ],
      [
        "Hypersensitivity (fever, rash, eosinophilia)",
        "Up to 30%231",
        "Unusual2"
      ],
      [
        "Temporal relationship with drug",
        "Positive231",
        "Negative2"
      ],
      [
        "HLA DRB1*03:01 or DRB1*04:01 association",
        "None236",
        "Common29"
      ],
      [
        "Concurrent autoimmune diseases",
        "Unusual187",
        "Present in 14%‐44%129"
      ],
      [
        "Cirrhosis at presentation",
        "Rare187",
        "28%‐33%9"
      ],
      [
        "Management",
        "Stop offending drug ± glucocorticoids187",
        "Glucocorticoids with AZA2"
      ],
      [
        "Relapse after drug withdrawal",
        "Rare187",
        "60%‐87%243"
      ],
      [
        "Progression to cirrhosis",
        "Rare187",
        "7%‐40%105"
      ],
      [
        "Survival without transplantation",
        "90%‐100%187",
        "10‐year survival, 89%‐91%105"
      ]
    ],
    "row_count": 11,
    "column_count": 3
  },
  {
    "table_index": 8,
    "headers": [
      "Medication",
      "Safety Reports in Pregnancy"
    ],
    "rows": [
      [
        "Terlipressin",
        "Uterine ischemia"
      ],
      [
        "Octreotide",
        "No harmful effects noted"
      ],
      [
        "Beta‐blockers",
        "Fetal bradycardia, fetal growth retardation"
      ],
      [
        "Lactulose",
        "No harmful effects noted"
      ],
      [
        "Rifaximin",
        "No harmful effects noted but limited data"
      ],
      [
        "Corticosteroids",
        "Inconsistent association with cleft abnormalities"
      ],
      [
        "AZA",
        "Premature birth"
      ],
      [
        "MMF",
        "Birth defects, spontaneous abortion"
      ],
      [
        "TAC",
        "Premature birth, transient neonatal renal dysfunction"
      ]
    ],
    "row_count": 9,
    "column_count": 2
  },
  {
    "table_index": 9,
    "headers": [
      "Drug",
      "Side Effects",
      "Management Options"
    ],
    "rows": [
      [
        "Predniso(lo)ne",
        "Cosmetic: Facial rounding, hirsutism, alopecia, dorsal hump, striaeSystemic: Weight gain, glucose intolerance/diabetes, hypertension, fatty liver, osteoporosis, vertebral compression, cataracts, glaucoma, opportunistic infectionsQuality of life: Emotional instability, psychosis, depression, anxiety",
        "Actively taper to the lowest steroid dose needed for remission and attempt withdrawal after remissionEye examinations for cataract and glaucomaLifestyle interventions for metabolic syndromeBone density monitoringVitamin D and calcium administrationProactive screening and management for quality of life and mental health symptoms"
      ],
      [
        "Budesonide",
        "Reduced intensity of the side effects from prednisone is possible despite first‐pass metabolismUnable to reach the liver with portal hypertensive shuntsPortal vein thrombosis in cirrhosis",
        "Taper budesonide to the lowest effective dose and attempt withdrawal after remissionDo not prescribe in cirrhosis and acute severe AIH"
      ],
      [
        "AZA",
        "Hematologic: Mild cytopenia, severe leukopenia or bone marrow failure (rare)Gastrointestinal: Nausea, emesis, pancreatitisNeoplastic: Nonmelanoma skin cancerCholestatic liver damage (rare)",
        "Check TPMT metabolizer status prior to prescribingMonitor cell counts at least every 6 monthsReduce dose if mild cytopenia occursDiscontinue in severe cytopeniaDiscontinue in gastrointestinal intoleranceAvoid direct sunlight and have yearly dermatologic screening for skin cancerNot recommended in decompensated cirrhosis or acute severe AIH"
      ]
    ],
    "row_count": 3,
    "column_count": 3
  },
  {
    "table_index": 10,
    "headers": [
      "Budesonide + AZA versus Predniso(ol)ne + AZA"
    ],
    "rows": [
      [
        "Biochemical remission",
        "Two studies (one RCT351and one non‐RCT20)",
        "High"
      ],
      [
        "Rapidity of response",
        "No studies reported rapidity of response",
        ""
      ],
      [
        "Side effects (bone disease, cytopenia, weight gain, portal vein thrombosis)",
        "One study351reported more steroid‐specific side effects in prednisone group compared to budesonide group",
        "Low"
      ],
      [
        "Death",
        "No studies reported death",
        ""
      ],
      [
        "Liver transplantation",
        "No studies reported LT",
        ""
      ],
      [
        "Meta‐analysis:I2test of heterogeneity",
        "I2= 0.0%,P= 0.495",
        ""
      ],
      [
        "Meta‐analysis for biochemical remission",
        "OR, 2.19; 95% CI, 1.30‐3.67",
        ""
      ],
      [
        "Meta‐analysis: Conclusions",
        "Few qualified studies"
      ],
      [
        "Homogeneous test results between studies"
      ],
      [
        "Current evidence insufficient to assess patient selection and long‐term outcome"
      ],
      [
        "Budesonide and AZA favored for biochemical remission"
      ],
      [
        "Conditional recommendation with low certainty for use of budesonide and AZA in children and adults without cirrhosis, acute severe hepatitis, or ALF"
      ]
    ],
    "row_count": 12,
    "column_count": 1
  },
  {
    "table_index": 11,
    "headers": [
      "Strength Determinant",
      "SR1: “First‐Line Treatment” (budesonide/AZA versus predniso(lo)ne/AZA",
      "SR2: “Second‐Line Treatment” (MMF versus TAC)",
      "SR3: “Steroid Withdrawal Post‐LT” (pred versus no pred)"
    ],
    "rows": [
      [
        "1. Benefits versus harms",
        "Budesonide > pred",
        "MMF > TAC",
        "No pred > pred"
      ],
      [
        "2. Certainty",
        "Limited",
        "Limited",
        "Limited"
      ],
      [
        "3. Cost",
        "High cost/copay for budesonide",
        "+MMF",
        "No pred"
      ],
      [
        "4. Patient values",
        "Budesonide",
        "+MMF (ease of use)",
        "No pred"
      ],
      [
        "+TAC (pregnancy)"
      ],
      [
        "5. Feasibility",
        "Copay may make it harder to get budesonide",
        "Equal",
        "Equal"
      ],
      [
        "6. Accessibility",
        "Copay may make it harder to get budesonide",
        "Equal",
        "Equal"
      ],
      [
        "7. Equity",
        "Equal",
        "Equal",
        "Equal"
      ]
    ],
    "row_count": 8,
    "column_count": 4
  },
  {
    "table_index": 12,
    "headers": [
      "MMF versus TAC"
    ],
    "rows": [
      [
        "Biochemical remission",
        "Two retrospective studies418reported no significant difference in frequency of biochemical remission",
        "Low"
      ],
      [
        "Drug intolerance",
        "One study418reported drug intolerance and showed no significant difference between MMF and TAC in frequency of side effects",
        "Very low"
      ],
      [
        "Death or LT",
        "One study418reported death or LT (together) and showed no significant difference in frequencies between MMF and TAC",
        "Very low"
      ],
      [
        "Meta‐analysis:I2test of heterogeneity",
        "I2= 59.6%,P= 0.116",
        ""
      ],
      [
        "Meta‐analysis: For biochemical remission",
        "OR, 1.95; 95% CI, 0.18‐20.81",
        ""
      ],
      [
        "Meta‐analysis: Conclusions",
        "Few qualified studies"
      ],
      [
        "Heterogeneous test results between studies"
      ],
      [
        "Low‐quality evidence to assess differences in frequency of biochemical remission"
      ],
      [
        "Very low‐quality evidence to assess differences in frequency of side effects, mortality, or need for LT"
      ],
      [
        "Conditional recommendation with very low certainty that MMF be used over TAC based on ease of use and side effect profile"
      ]
    ],
    "row_count": 10,
    "column_count": 1
  },
  {
    "table_index": 13,
    "headers": [
      "Continuation versus Discontinuation of Steroids After LT"
    ],
    "rows": [
      [
        "Recurrent autoimmune hepatitis",
        "Two retrospective studies488and one RCT489reported no significant difference in recurrence of AIH after LT",
        "Low"
      ],
      [
        "Acute cellular rejection",
        "No studies reported frequencies of acute cellular rejection",
        ""
      ],
      [
        "Graft loss",
        "No studies reported frequencies of graft loss",
        ""
      ],
      [
        "Death",
        "One RCT489reported no significant difference between the two groups",
        "Very low"
      ],
      [
        "Re‐transplantation",
        "No studies reported retransplantation",
        ""
      ],
      [
        "Meta‐analysis:I2test of heterogeneity",
        "I2= 38.6%,P= 0.202",
        ""
      ],
      [
        "Meta‐analysis: For biochemical remission",
        "OR, 0.62; 95% CI, 0.19‐1.96",
        ""
      ],
      [
        "Meta‐analysis: Conclusions",
        "Few qualified studies"
      ],
      [
        "Heterogeneous test results between studies"
      ],
      [
        "Low‐quality evidence to assess differences in frequency of recurrent AIH after LT"
      ],
      [
        "Very low‐quality evidence to assess differences in mortality after LT"
      ],
      [
        "Conditional recommendation of very low certainty that steroids be discontinued after LT"
      ]
    ],
    "row_count": 12,
    "column_count": 1
  },
  {
    "table_index": 14,
    "headers": [
      "Categories",
      "Recurrent AIH",
      "De NovoAIH"
    ],
    "rows": [
      [
        "Clinical findings",
        "Graft dysfunction at 2 months‐12 years471",
        "Indication for LT other than AIH503"
      ],
      [
        "Asymptomatic to graft failure614",
        "Exclude plasma cell–rich rejection/plasma cell hepatitis521"
      ],
      [
        "May be detected only by liver biopsy500",
        ""
      ],
      [
        "Laboratory findings",
        "Increased serum AST, ALT, IgG levels501",
        "Increased serum AST, ALT, IgG levels503"
      ],
      [
        "Serological markers",
        "Same antibodies as pre‐LT AIH617",
        "ANA, SMA, anti‐LKM1503"
      ],
      [
        "ANA, SMA common617"
      ],
      [
        "Anti‐LKM1 rare618"
      ],
      [
        "Histologic findings",
        "Lobular hepatitis, focal necrosis, pseudorosettes (early)620",
        "Interface hepatitis521"
      ],
      [
        "Interface hepatitis, lymphoplasmacytic infiltration (late)623",
        "Lymphoplasmacytic infiltrates521"
      ],
      [
        "Lobular collapse, confluent/bridging necrosis (severe)621",
        ""
      ],
      [
        "Treatment",
        "Predniso(lo)ne, 30 mg daily, and AZA, 1‐2 mg/kg daily499",
        "Children501Predniso(lo)ne (1‐2 mg/kg, <60 mg daily) and AZA (1‐2 mg/kg daily)Otherwise same as recurrent AIH adults501Same as recurrent AIH"
      ],
      [
        "Predniso(lo)ne dose reduction to 5‐10 mg daily in 4‐8 weeks624"
      ],
      [
        "Predniso(lo)ne and AZA maintenance501"
      ],
      [
        "Continue calcineurin inhibitor624"
      ],
      [
        "Rescue regimens (empiric)",
        "MMF for AZA627",
        "MMF for AZA419"
      ],
      [
        "Switch calcineurin inhibitor498",
        "Rapamycin629"
      ],
      [
        "Rapamycin628",
        ""
      ],
      [
        "Outcomes",
        "5‐year patient survival, 86%‐100%500",
        "Better in children than adults503"
      ],
      [
        "Graft failure, 8%‐50%614",
        "Biochemical remission, 86%503"
      ],
      [
        "Retransplantation, 33%‐60%614",
        "Retransplantation, 8%508"
      ],
      [
        "Recurrent AIH in retransplanted liver, 33%‐100%614",
        "Patient survival, 95%626"
      ]
    ],
    "row_count": 21,
    "column_count": 3
  },
  {
    "table_index": 15,
    "headers": [
      "Goal",
      "Treatment",
      "Mechanism of Action",
      "Status of Development"
    ],
    "rows": [
      [
        "Decrease the numbers and/or functions of autoimmune effector cells and pathogenic autoantibodies",
        "Immunosuppressive drugs: CNI, mTOR, antiproliferative agents",
        "Inhibit proliferation of autoantigen‐activated CD4 and CD8 T cells by reducing the amount and/or signaling of mitogenic IL‐2 or block completion of T‐cell division",
        "SOC in multiple AI diseases. Combination therapies using subtoxic doses of two or more agents attractive. Ongoing research into prevention and management of toxicities"
      ],
      [
        "Anti‐CD20",
        "B‐cell depletion"
      ],
      [
        "Anti‐BAFF",
        "B‐cell depletion followed by mobilization of memory B cells from lymphoid tissue. Potent inhibition of BAFF signaling in activated T cells",
        "Off‐label use as alternative therapy in AIH"
      ],
      [
        "Anti‐BAFF, followed by anti‐CD20",
        "SOC in SLE. Ongoing clinical trial in AIH"
      ],
      [
        "Anti‐CD40",
        "Depletion of memory B cells mobilized from lymphoid tissues by anti‐BAFF",
        "Clinical trials planned in AI diseases"
      ],
      [
        "Efgartigimod",
        "Block CD40‐CD40L (CD154) costimulation of T cells and B cells",
        "POC. Clinical trial initiated in liver transplantation"
      ],
      [
        "Inhibition of sphingosine‐1‐phosphate receptors",
        "First in class antibody fragment to block FcRn to increase IgG clearance and prevent IgG recycling",
        "POC to reduce pathogenic autoantibodies and Ig–autoantigen immune complexes"
      ],
      [
        "Myeloid‐derived suppressor cells",
        "Prevent egress of activated T cells from lymph nodes into blood",
        "SOC in MS, new agents in development for other AI diseases"
      ],
      [
        "Inhibit autoreactive T‐cell activation and proliferation",
        "POC in preclinical models. Clinical trials planned in RA"
      ],
      [
        "Decrease and/or inhibit proinflammatory cytokines",
        "Anti‐TNFα or TNFα‐receptor",
        "Reduce TNFα‐mediated tissue injury and proinflammatory signaling pathways",
        "SOC in multiple AI diseases. Studied as an alternative therapy in AIH"
      ],
      [
        "Anti‐IL‐6 or anti‐IL‐6R",
        "Reduce pathogenic effects of proinflammatory IL‐6 signaling in innate and adaptive immune responses",
        "SOC in RA, clinical trials ongoing in other AI diseases"
      ],
      [
        "Anti‐IL‐12 (p40 subunit)",
        "Reduce pathogenic effects of proinflammatory IL‐12 signaling in innate and adaptive immune responses",
        "SOC in psoriasis and Crohn’s disease. Also blocks IL‐23 signaling"
      ],
      [
        "Anti‐IL‐17a or Anti‐17R",
        "Reduce pathogenic effects of IL‐17",
        "SOC for psoriasis and psoriatic arthritis. Clinical trials planned in other AI diseases"
      ],
      [
        "Anti‐IL‐21",
        "Reduce multiple pathogenic effects of IL‐21 in innate and adaptive immune responses",
        "Ongoing clinical trials in RA, T1DM, and Crohn’s disease"
      ],
      [
        "Anti‐IL‐23 (p19 or p40 subunits)",
        "Reduce pathogenic effects of proinflammatory IL‐23 stimulation of Th17 cells",
        "SOC in psoriasis and Crohn’s disease"
      ],
      [
        "Anti‐Blys",
        "Reduce pathogenic B‐cell selection, differentiation, and homeostasis",
        "SOC in SLE"
      ],
      [
        "Inhibit signaling of proinflammatory cytokines",
        "mTOR inhibition",
        "Decrease proliferation of activated CD4 and CD8 T cells by inhibiting signaling of IL‐2",
        "SOC in solid organ transplantation and AI diseases. Alternative therapy in AIH"
      ],
      [
        "Tofacitinib (JAK3 inhibitor of IL‐2 signaling)",
        "Decrease proliferation of activated CD4 and CD8 T cells by inhibiting signaling of IL‐2",
        "SOC in RA. Clinical trials planned"
      ],
      [
        "Baricitinib (JAK1/2 inhibitor of IL‐6 and IFNγ signaling)",
        "Reduce pathogenic effects of proinflammatory IL‐6 signaling through IL‐6R in innate and adaptive immune responses and pathogenic effects of IFNγ signaling in NK, NK T, CD4, and CD8 T cells",
        "SOC in RA. Ongoing clinical trial in PBC"
      ],
      [
        "Pacritinib (JAK2 inhibitor of IL‐12/IL‐23 signaling)",
        "Reduce proinflammatory IL‐12 and Il‐23 signaling that polarizes increases CD4 Th1 polarization, secretion of IFNγ and TNFα, cytotoxic activity of NK and CD8 CTLs, and differentiation of pathogenic Th17 cells",
        "POC established. Ongoing clinical trials"
      ],
      [
        "Filotinib (JAK1 inhibitor of IFNα/IFNβ signaling)",
        "Reduce immunopathogenic gene expression induced by type 1 IFNs",
        "POC established. Ongoing clinical trials"
      ],
      [
        "Upadacitinib (selective JAK1 inhibitor of IFNα/IFNβ signaling)",
        "Reduce immunopathogenic gene expression",
        "SOC for refractory RA"
      ],
      [
        "Augment effects of immunosuppressant cytokines",
        "rHuIL‐10",
        "Reduce immunopathogenic effects of activated CD4 Th1 cells",
        "SOC to prevent pancreatitis post‐ERCP"
      ],
      [
        "Trial in UC terminated for concern of Guillain‐Barré syndrome"
      ],
      [
        "Inhibit transendothelial migration of effector cells from blood into tissues",
        "Inhibition of chemokine receptors or integrins",
        "Prevent tissue inflammation and injury by blocking transendothelial entry of effector cells from blood into target tissues",
        "SOC inhibition of α4/β7 integrin in UC. Clinical trial in PSC ineffective"
      ],
      [
        "Prevent chemokine‐induced terminal differentiation of effector cells",
        "Potential for clinical trials of other Food and Drug Administration–approved chemokine/integrin inhibitors"
      ],
      [
        "Establish immunoregulatory control",
        "Low‐dose IL‐2 infusion to increase autoantigen‐specific iTregs",
        "Expansion of preexisting autoantigen‐specific iTregsin vivorequires exposure to low concentrations of IL‐2",
        "POC established"
      ],
      [
        "Clinical trials ongoing"
      ],
      [
        "Infusion of autoantigen‐specific iTregs generatedex vivo",
        "Ex vivogeneration of autologous autoantigen‐specific iTregs followed by infusion to immunologically control autoantigen‐specific CD4 Th‐cell subset responses",
        "POC of iTreg generationex vivoestablished. Future clinical trials planned in AIH. Viability, function, and distribution of iTregs after infusion unknown"
      ],
      [
        "Inhibition of bromodomain and extraterminal family of proteins",
        "Inhibition of disease‐specific epigenetic transcriptional enhancers, superenhancers, and enhancer RNA production to decrease autoimmune reactions",
        "POC established. Clinical trials ongoing"
      ],
      [
        "Mesenchymal stem cells",
        "Inhibition of innate immune cells, effector T cells",
        "POC established. Clinical trials ongoing"
      ],
      [
        "Induction of antigen‐specific iTregs"
      ],
      [
        "Reduction of TNFα secretion"
      ],
      [
        "Establish physiologic immunoregulatory state of pregnancy",
        "PIF",
        "Creation of immunosuppressive and immunomodulatory environment of pregnancy",
        "Phase 1b trial of synthetic PIF in AIH completed. Ongoing clinical trial"
      ]
    ],
    "row_count": 34,
    "column_count": 4
  }
]